MTDH通过介导ETS-1乙酰化修饰激活Wnt/β-catenin信号通路进而促进胆囊腺癌干细胞干性维持
批准号:
82103678
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
刘子儒
依托单位:
学科分类:
肿瘤干细胞
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
刘子儒
中文摘要
胆囊腺癌是最常见的胆道恶性肿瘤。肿瘤干细胞是肿瘤组织中的少量具有自我更新、无限增殖及多向分化潜能的细胞,是肿瘤发生、发展、侵袭和转移的根源。基于前期已初步证实“MTDH 可通过调控β-catenin参与胆囊腺癌CSCs干性维持”、“ MTDH可通过ETS-1调控胆囊腺癌肿瘤干细胞干性”及“ MTDH通过作用CBP提高组蛋白乙酰化修饰进而调控ETS-1表达”,推测MTDH通过介导ETS-1乙酰化修饰激活Wnt/β-catenin信号通路进而促进胆囊腺癌干细胞干性维持。应用胆囊腺癌干细胞为模型,深入研究MTDH调控ETS-1的分子机制以及ETS-1通过调控FXOM1激活Wnt/β-catenin通路,进而影响其干性维持与自我更新,细胞增殖、侵袭、迁移能力及体外成瘤能力。可望阐明MTDH作为胆囊癌干细胞标志物及其作用机制,发现潜在的治疗靶标和诊断标志物,有望为临床诊断和治疗提供新策略和方法。
英文摘要
Gallbladder cancer is common primary malignant tumor of the digestive system. Cancer stem cells (CSCs) are cancer cells that possess characteristics associated with normal stem cells, specifically the ability to generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. CSCs are the root of tumor occurrence, development, invasion and metastasis. Basing on our previous study, we have preliminarity confirmed that: MTDH facilitates to maintain the CSCs stemness of gallbladder cancer via reugulating β-catenin, MTDH contributes to maintain the CSCs stemness of gallbladder cancer via upregulating ETS-1, MTDH may upregulates the expression of ETS-1 by enhancing histone acetylation mediate by CBP, and Ets-1 activates the Wnt/β-catenin pathway through up-regulating FOXM1 expression. Thus we speculated that MTDH facilitates maintaining the stemness of gallbladder adenocarcinomas stem cells through activation Wnt/β-catenin pathway mediated by ETS-1 acethylation. we will use gallbladder adenocarcinoma CSCs as model to further explore the molecular mechanism of MTDH regulating ETS-1, and Ets-1 activates the Wnt/β-catenin pathway via FXOM1, thus affecting its stemness maintenance and self-renewal, cell proliferation, invasion, migration and tumorigenesis in vitro. This study is expected to clarify that MTDH can be used as a biomarker of gallbladder cancer CSCs and the underline mechanism, and to find potential therapeutic targets and diagnostic markers, suggesting providing new strategies and methods for clinical diagnosis and treatment.
本研究聚焦于胆囊癌干细胞(CSCs)的干性特征及其调控机制。研究发现,干细胞标志物CD133阳性细胞中,MTDH(Metadherin)的表达水平显著高于CD133阴性细胞。通过干扰和过表达MTDH,观察到MTDH沉默能抑制CD133阳性细胞的成球能力,而过表达MTDH则增强了这一能力。此外,MTDH过表达还能提高CD133阳性细胞的克隆形成、侵袭和迁移能力,而干扰MTDH则抑制这些能力。进一步分析显示,MTDH过表达后干细胞标志物表达水平提高,沉默后则下调,表明MTDH可能参与调控胆囊癌干细胞的干性特征。研究还发现,MTDH可能通过调控β-catenin参与胆囊癌CSCs干性维持,且MTDH过表达导致β-catenin入核增多,干扰MTDH则减少。通过基因表达数据集分析,确定了MTDH正向调控的三个基因:ETS1、RUBCN和DDX3Y,其中ETS1表达差异最为显著。沉默MTDH过表达细胞中的ETS-1,可以抑制MTDH对干细胞自我更新的促进效果,且MTDH促进干细胞标志物表达的作用可被ETS-1沉默后所抑制,提示MTDH可能通过ETS1调控胆囊癌肿瘤干细胞干性。此外,研究还探讨了APEX1在胆囊癌中的作用,发现APEX1在GBC组织中表达上调,并与GBC的侵袭性临床病理特征及不良预后相关。APEX1是影响GBC预后的独立危险因素,且在CD133阳性GBC-SD细胞中过表达。APEX1基因敲除能显著抑制细胞增殖、迁移和侵袭,并促进体外细胞凋亡。研究推测APEX1可能通过上调CD133阳性GBC-SD细胞中的Jagged 1影响这些恶性特性,表明APEX1是一个有前途的预后生物标志物,也是GBC的潜在治疗靶点。综上所述,本研究揭示了MTDH和APEX1在胆囊癌干细胞干性维持中的作用及其潜在的分子机制,为胆囊癌的诊断和治疗提供了新的视角和靶点。
国内基金
海外基金